|
#
|
Title
|
Authors
|
Affiliations
|
Keywords
|
|
P143
|
T-cell metabolic insufficiency explains the dysfunctional immune response in renal cell carcinoma
|
Nicola Annels1, Michael Denyer1, David Nicol2, Muddassar Hussain3, Anna Silvanto3, Hardev Pandha1
|
1University of Surrey, Guildford, United Kingdom 2The Royal Marsden Hospital, London, United Kingdom 3Frimley Park Hospital, Camberley, United Kingdom
|
Tumor microenvironment | Metabolism | Solid tumors | Tumor infiltrating lymphocytes (TILs)
|
|
P144
|
Investigating the Kynurenine pathway as a Central Effector Mechanism of Tumor Immune-suppression and its Potential as Therapeutic Target
|
Luis Felipe Campesato1, Sadna Budhu1, X. Michelle Zhang2, Mark G. Manfredi2, Karen McGovern2, Jedd D. Wolchok1, Taha Merghoub1
|
1Memorial Sloan-Kettering Cancer Center, New York, NY, USA 2Kyn Therapeutics, Cambridge, MA, USA
|
Immune tolerance | Myeloid cells | Tumor microenvironment | Immune suppression | Monocyte/Macrophage | Metabolism | Solid tumors | Tumor evasion | Checkpoint blockade | Regulatory T cell (Treg)
|
|
P145
|
CD38-NAD+ Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response
|
Shilpak Chatterjee1, Anusara Daenthanasanmak1, Paramita Chakraborty1, Megan Wyatt1, Chrystal Paulos1, Xue-Zhong Yu1, Shikhar Mehrotra1
|
1MUSC, Charleston, SC, USA
|
Adoptive immunotherapy | T cell | Metabolism | Solid tumors
|
|
P146
|
Co-expression of CD39 and CD103 identifies tumor-reactive CD8 TIL in human solid tumors
|
Thomas Duhen1, Rebekka Duhen1, Ryan Montler1, Tarsem Mougdil1, Bernard A. Fox1, Christopher Dubay1, Shu-Ching Chang3, Gary Grunkemeier3, Jason McDermott4, Rom Leidner1, Richard B Bell1, Andrew D Weinberg1
|
1AgonOx, Portland, OR, USA 3Medical Data Research Center, Providence Health & Services, Portland, OR, USA 4Pacific Northwest National Laboratory, Richland, WA, USA
|
Adoptive immunotherapy | Neoantigens | Tumor antigens | Solid tumors | T cell | Tumor infiltrating lymphocytes (TILs) | Checkpoint blockade
|
|
P147
|
Reduced tumor-associated glycosphingolipids in cell membrane lipid rafts and a diminished proliferation rate in mammary breast carcinoma cultures after incubation with glyphosate-based formulations
|
Beatrix Kotlan1, Gabriella Liszkay1, Orsolya Csuka1, Jozsef Toth1, Marianna Olah2, Miklos Kasler1, Andras Szekacs2
|
1National Institute of Oncology, Budapest, Hungary 2Agro-Environmental Research Institute, National Agricultural Research and Innovation Centre, Budapest, Hungary
|
Bioinformatics | Carcinogenesis | Biomarkers | Epidemiology | Immune toxicity | Leukemia/Lymphoma | Tumor antigens | Immune adjuvant | Solid tumors
|
|
P148
|
KHK2455, a long-acting selective IDO-1 inhibitor, in combination with mogamulizumab, an anti-CCR4 monoclonal antibody, in patients with advanced solid tumors: preliminary safety report and pharmacodynamic activity from a first-in-human study
|
Solmaz Sahebjam1, Timothy Yap2, David Hong2, Arpit Rao3, Sarah Adams3, Sergey Efuni4, Dmitri Grebennik4, Denis Healy4, Eniola Ogunmefun4, Yi Liu4, Tomonori Tayama4, Olivier Rixe3
|
1Moffitt Cancer Center and Research Institute and the University of South Florida, Tampa, FL, USA 2The University of Texas MD Anderson Cancer Center, Houston, TX, USA 3University of New Mexico Comprehensive Cancer Center, Albuquerque, NM, USA 4Kyowa Kirin Pharmaceutical Development Inc., Princeton, NJ, USA
|
Regulatory T cell (Treg) | Clinical study | Metabolism | Chemokine | Clinical trial | Solid tumors
|
|
P149
|
In vitro and in vivo characterization of KHK2455, a highly potent and selective indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor with a novel mechanism of action
|
Motoya Mie1, Kana Kunieda1, Shoko Koshiba1, Takashi Murakami2, Shinya Horita1, Yuichi Fukuda1, Toshihiko Ishii1, Ryuichiro Nakai1, Kazuyasu Nakamura3
|
1Kyowa Hakko Kirin Co., Ltd., Sunto-gun, Japan 2Saitama Medical University, Iruma-gun, Japan 3Kyowa Hakko Kirin Co., Ltd., Tokyo, Japan
|
Tumor microenvironment | Biomarkers | Metabolism | T cell | Costimulation | Tumor stroma | Tumor evasion
|
|
P150
|
Immunomodulatory effects of the senescence-associated secretory phenotype on NK cells in renal cell carcinoma
|
Andreas Lundqvist1, Ann-Kathrin Prinz1, Kevin Bohanek1, Kristina Witt1
|
1Karolinska Institutet, Stockholm, Sweden
|
Adoptive immunotherapy | NK/NK T cell | Chemotherapy | Immune suppression | Solid tumors
|
|
P151
|
Profiling the immunogenic cell death (ICD) mechanisms induced by Nano-Pulse Stimulation (NPS) treatment in mouse B16-F10 melanoma tumors using NanoString technology
|
Amanda McDaniel1, Snjezana Anand2, Aman Alzubier1, Juliette Berlin1, Holly Hartman1, Darrin Uecker1, Richard Nuccitelli1
|
1Pulse Biosciences, Hayward, CA, USA 2Pulse Biology, Hayward, CA, USA
|
Antigen presenting cells | Dendritic cell | Inflammation | TLR | Tumor antigens | Cytokine | Gene expression | T cell | Solid tumors
|
|
P152
|
41BB costimulation enables PD-1 blockade therapy by inducing T cell mitochondrial function and biogenesis
|
Ashley Menk1, Nicole Scharping1, Deanna Dunstane1, Greg Delgoffe1
|
1University of Pittsburgh, Pittsburgh, PA, USA
|
Costimulation | Metabolism | Checkpoint blockade | Tumor infiltrating lymphocytes (TILs) | T cell
|
|
P153
|
Nanoparticles to target tumor-draining lymph nodes conjugated with an antagonist for vasoactive intestinal peptide to promote an anti-tumor immune response
|
Rebecca Pankove1, Sruthi Ravindranathan1, Parvin Forghani1, David Francis2, Susan Thomas2, Edmund Waller1
|
1Emory University, Atlanta, GA, USA 2Georgia Institute of Technology, Atlanta, GA, USA
|
T cell lineages | Checkpoint blockade | Coinhibition | Tumor antigens | Immune adjuvant | T cell | Solid tumors | NK/NK T cell
|
|
P154
|
Tumor-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis in acute promyelocytic leukemia
|
Sara Trabanelli1, Mathieu Chevalier2, Amaia Martinez Usatorre1, Alejandra Gomez-Cadena1, Bérengère Salomé1, Mariangela Lecciso3, Valentina Salvestrini3, Gabriela Baerlocher4, Carmelo Carlo-Stella5, Daniela Taurino5, Armando Santoro5, Orietta Spinelli6, Alessandro Rambaldi6, Emanuela Giarin7, Giuseppe Basso7, Cristina Tresoldi8, Fabio Ciceri11, Luca Mazzarella10, Pier Giuseppe Pelicci10, Andrew Mc Kenzie9, Dominique Vanhecke1, Domenico Mavilio12, Antonio Curti3, George Coukos1, Laurent Derré2, Camilla Jandus1
|
1Ludwig Institute for Cancer Research, University of Lausanne, Epalinges, Switzerland 2Lausanne University Hospital (CHUV), Lausanne, Switzerland 3Institute of Hematology Seràgnoli, University of Bologna, Bologna, Italy 4Bern University Hospital, University of Bern, Bern, Switzerland 5Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano-Milan, Italy 6Ospedale Papa Giovanni XXIII, Bergamo, Italy 7Clinica di Oncoematologia Pediatrica, University of Padova, Padova, Italy 8Laboratorio Ematologia Molecolare, Biobanca Neoplasie Ematologiche, San Raffaele Hospital, Milano, Italy 9MRC laboratory of molecular biology, Cambridge, United Kingdom 10European Institute of Oncology, Milan, Italy 11San Raffaele Hospital, Milano, Italy 12Humanitas Clinical and Research Center, Rozzano-Milan, Italy
|
Cytokine | Leukemia/Lymphoma | Tumor microenvironment | Carcinogenesis | MDSC | NK/NK T cell
|
|
P155
|
Targeting CSK kinase activity to enhance anti-tumor immunity
|
Cindy Wang, Carolyn Cao, Lisa Berman-Booty, Jesse Swanson, Rukiye Eraslan, Miguel Sanjuan, Gregory Vite, Lan-Ying Qin, John Hunt, Bryan Fink, Susan Wee
|
Bristol-Myers Squibb
|
Checkpoint blockade | T Cell
|
|
P156
|
Immunometabolic requirements for T cell exhaustion
|
Nicole Scharping1, Ashley Menk1, Dayana Rivadeneira1, Greg Delgoffe1
|
1University of Pittsburgh, Pittsburgh, PA, USA
|
Tumor microenvironment | Immune suppression | Metabolism | Solid tumors | T cell | Tumor infiltrating lymphocytes (TILs)
|
|
P157
|
Mitochondrial Reactive Oxygen Species are a Biomarker of Metabolic Fitness of T Cells in Tumors
|
Jessica Thaxton1
|
1Medical University of South Carolina, Charleston, SC, USA
|
T cell | Tumor infiltrating lymphocytes (TILs) | Solid tumors | Metabolism | Checkpoint blockade
|
|
P158
|
PBMC-humanized preclinical tumor models serve as a valuable platform to evaluate in vivo activities of novel immune-oncology drug candidates
|
Lan Zhang1, Juan Zhang2, Meng Qiao1, Xuefei Yan1, Jian Ding1, Fei Chen1, Xiaoyu An3, Weibin Tan4, Xiaoyan Fu4, WenQing Yang1, Qian Shi1
|
1CrownBio Science, Inc, Santa Clara, CA, USA 2Cstone Biopharma, Santa Clara, CA, USA 3CrownBio Science Inc, Taicang, China 4Taicang Blood Center, Taicang, USA
|
Biomarkers | Adoptive immunotherapy | Solid tumors | Checkpoint blockade
|
|
P159
|
Clinical features and outcomes with talimogene laherparepvec in melanoma patients with comorbidities: a single-center experience
|
Alice Zhou1, Daniel Wang1, Deborah Wallace1, Douglas Johnson1, Kristin Ancell1
|
1Vanderbilt University Medical Center, Nashville, TN, USA
|
Clinical study | Immune toxicity | Inflammation
|